| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We developed a novel, rapid epidermal growth factor receptor gene (EGFR) mutation assay using a real-time droplet-polymerase chain reaction machine (EGFR d-PCR assay). The purpose of this study was to validate the performance of the EGFR d-PCR assay using fresh liquid cytology specimens (FLCSs) from lung cancer patients. We analyzed three major EGFR mutations in 80 FLCSs via the EGFR d-PCR assay and conventional real-time PCR assay. In addition, we performed sensitivity assays using cell lines with EGFR mutations. The EGFR d-PCR assay accurately detected 3 major EGFR mutations compared to conventional real-time PCR assay, resulting in concordant between the two assays. In addition, EGFR d-PCR assay could reduce reaction time (8 min and 10 s). Sensitivity of the EGFR d-PCR assay was 0.05-0.5%. In conclusion, the EGFR d-PCR assay markedly reduced the detection time of major EGFR mutations with high sensitivity compared with the conventional assay.
|
